• Service
  • Resources
    • Webinars
    • Upcoming Events
    • Documents Download
    • FAQ
    • NMPA Approval Report
  • News
  • CER
  • About
Subscribe

Our Services

Strategy Consulting

  • Market Entry Strategy
  • Regulatory Strategy
  • Clinical Strategy
  • China Localization Strategy
  • Hainan Urgent Use Pathway
  • Innovation Pathway
  • Fast Track Pathway
  • Digital Health Consulting

Registration Affairs

  • Pre-market Registration
  • Modification Registration
  • Renewal Registration
  • Request for Classification
  • Legal Agent Representation
  • NMPA Expert Panel Meeting
  • NMPA Supplemental Notice

Quality Assurance

  • Postmarket Surveillance Compliance (IFU, Label, GSP)
  • Adverse Event Reporting
  • Recall Handling
  • Periodic Risk Evaluation Report
  • Annual QMS Self-Inspection Report
  • NMPA Inspections & Mock-Audit
  • QMS Establishment/Audit/Remediation
  • QA Gap Analysis
  • Factory Audit
  • Unique Device Identifier

Device Testing

  • China Local Type Testing
  • Device Modification Compliance Testing
  • Biocompatibility Testing
  • EMC Testing

Clinical Research Organization (CRO)

  • Clinical Trials/Research
  • Real-World Study
  • China CER & MDR CER
  • Clinical Evaluation Feasibility Assessment

Customized Training

  • China Regulatory Training
  • China QMS Training
  • China GCP Training
  • China Localization Training
  • Periodic Regulatory Updates Training

Other Services

  • Translation
  • Patent & Trademark
  • Distributor Evaluation & Audit
  • KOL Interview/Consultation
  • Investment
  • Global regulatory services
  • Service
  • Resources
    • Resources
    • Webinars
    • Upcoming Events
    • Documents Download
    • FAQ
    • NMPA Approval Report
  • News
  • About
  • CER
  • Subscribe
  • CN
  • US
  • Home
  • China GMP/GSP/NMPA Onsite Inspections
  • Webinars

Webinars


  • Webinars
  • Revisiting Order 739
  • Order 739
  • Clinical Evaluation
  • QMS&PMS
  • Respiratory Registration
  • China GMP/GSP/NMPA Onsite Inspections
  • Short Videos
  • China Localization

Part 2 Measures For Supervision And Adminstration Of Medical Device Production (China GMP) And Key Aspects Of Onsite Inspections.

2022-01-21

To better understanding China GMP, the speaker used a tablle to list corresponding main items for ISO 13485:2016).…

READ MORE >

Part 1 Introduction The Webinar——Keep Up With The Enhancement Of Medical Device Post-Market Surveillance In China: GMP, GSP, And NMPA Onsite Inspections

2022-01-21

Introduction to the regulations The speaker introduces the development of of medical device regulations in China which are…

READ MORE >

Part 7 Stricter Post-market Surveillance Requirements And MAH’s Responsibilities Under Order 739

2021-11-23

This session of the webinar introduces the Stricter post-market surveillance requirements and MAH’s responsibilities under order 739. In…

READ MORE >

Part 6 Comparing CER Draft Vs Final Guidance

2021-11-23

This session of the webinar briefly compares CER draft vs final guidance. The speaker use a table to…

READ MORE >

Part 5 Major Changes To Clinical Evaluation Under Order 739

2021-11-23

This session of the webinar introduces the major changes to clinical evaluation under order 739. The speaker review…

READ MORE >

Part 4 Major Changes To Renewal & Modification Under Order 739

2021-11-23

This session of the webinar introduces the major changes to renewal & modification under order 739. The speaker…

READ MORE >

Part 3 Major Changes To Type Testing Under Order 739

2021-11-23

This session of the webinar introduces the major changes to to type testing under order 739. The speaker…

READ MORE >

Part 2 Major Changes To Registration Dossier Under Order 739

2021-11-23

This session of the webinar introduces the major changes to registration dossier under 739. The speaker shows a…

READ MORE >

Part 1 Revisiting Order 739

2021-11-23

This session of the webinar introduces the background of order 739. The speaker introduces the hierarchy of NMPA…

READ MORE >

Part 7 Draft And Submit Periodic Risk Evaluate Report (PREP) To China NMPA

2021-10-01

This session of the webinar introduces the draft and submit periodic risk evaluate report (PRER) to China NMPA.…

READ MORE >

Part 6 Adverse Event Reporting Management Under Order 739

2021-10-01

This session of the webinar introduces the adverse event reporting management under order 739. The speaker list article…

READ MORE >

Part 5 How To Choose Distributors Who Are Compliant With NMPA Requirements In China?

2021-10-01

This session of the webinar introduces how to choose distributors who are compliant with NMPA requirements in China.…

READ MORE >

Prev12345Next
Twitter Linkedin
United States
Email: info@bradyknowsmedical.com
Phone: +86 18600392020
China
Beijing Office: Room 1501-1502, East Ocean Centre, No. 24 A, Jianguomenwai Avenue, Chaoyang District, Beijing, China
Shanghai Office: Lingang New Zone, China (Shanghai) Pilot Free Trade Zone
Hainan Office: Boao Lecheng pilot zone of international medical tourism, Qionghai City, Hainan Province
Email: info@bradyknowsmedical.com
Phone: +86 18600392020 +86 10 65155991

©2025 Bradynuoen Beijing PharmTech Co Ltd All Rights Reserved.

京ICP备15042665号-7